Ocugen, Inc. (OCGN) stock
OCGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.83−0.05 (-5.24%)
Close on Nov 13, 2026Market cap $280.72MP/E –Yield –
Ocugen operating margin
Operating margin is operating income as a percentage of revenue.
Ocugen's operating margin for the twelve months ending Sep 30, 2025 was -1112.9%. For fiscal 2025 it was -1425.7%, against -1350.4% the year before. The highest annual figure on record is -1085.7% in fiscal 2023.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -1425.7% | −75.3 |
| FY2024 | Dec 31, 2024 | -1350.4% | −264.7 |
| FY2023 | Dec 31, 2023 | -1085.7% | +2494.4 |
| FY2022 | Dec 31, 2022 | -3580.0% | +45920.0 |
| FY2020 | Dec 31, 2020 | -49500.0% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -909.9% | +94.8 |
| Q2 FY2026 | Jun 30, 2026 | -1105.1% | −126.0 |
| Q1 FY2026 | Mar 31, 2026 | -1163.7% | +647.9 |
| Q3 FY2025 | Sep 30, 2025 | -1006.0% | +160.6 |
| Q2 FY2025 | Jun 30, 2025 | -1004.7% | +349.3 |
| Q1 FY2025 | Mar 31, 2025 | -979.1% | +225.6 |
| Q4 FY2024 | Dec 31, 2024 | -1811.5% | −993.6 |
| Q3 FY2024 | Sep 30, 2024 | -1166.5% | −830.5 |
| Q2 FY2024 | Jun 30, 2024 | -1354.0% | +3499.6 |
| Q1 FY2024 | Mar 31, 2024 | -1204.7% | +2866.4 |
| Q4 FY2023 | Dec 31, 2023 | -818.0% | +1839.0 |
| Q3 FY2023 | Sep 30, 2023 | -336.1% | +5052.3 |
| Q2 FY2023 | Jun 30, 2023 | -4853.6% | −1498.1 |
| Q1 FY2023 | Mar 31, 2023 | -4071.1% | −265.1 |
| Q4 FY2022 | Dec 31, 2022 | -2657.0% | +5170.9 |
| Q3 FY2022 | Sep 30, 2022 | -5388.4% | – |
| Q2 FY2022 | Jun 30, 2022 | -3355.5% | – |
| Q1 FY2022 | Mar 31, 2022 | -3806.0% | – |
| Q2 FY2020 | Jun 30, 2020 | -7827.9% | – |
See a number that looks wrong?